Specialty medical injectable drug program, requirements and drug policy updates: Byooviz™
New specialty medical injectable guidelines and requirements announced.
June 16, 2022
- All states
Please review the following table to determine changes to our specialty medical injectable drug programs.
|Drug Name||UnitedHealthcare Commercial||Treatment Uses|
|X||Indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization.|
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
For questions, please contact your broker or UnitedHealthcare representative.
More updates for your business
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.